4
Participants
Start Date
September 3, 2021
Primary Completion Date
January 10, 2022
Study Completion Date
January 10, 2022
Niclosamide
Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
Placebo
The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Klinische Forschung Berlin-Mitte GmbH, Berlin
Klinische Forschung Dresden GmbH, Dresden
Klinische Forschung Hamburg GmbH, Hamburg
Lead Sponsor
UNION therapeutics
INDUSTRY